Document is current
Any future updates will be listed below
-
Authors
Dong, Yixing https://orcid.org/0009-0003-5115-5686
Saglietti, Chiara
Bayard, Quentin https://orcid.org/0000-0001-9270-2015
Espin Perez, Almudena
Carpentier, Sabrina
Buszta, Daria https://orcid.org/0009-0002-9874-9791
Tissot, Stephanie https://orcid.org/0000-0003-3080-4598
Dubois, Rémy
Kamburov, Atanas
Kang, Senbai
Haignere, Carla
Sarkis, Rita https://orcid.org/0000-0003-4874-9937
Andre, Sylvie
Alexandre Gaveta, Marina
Lopez Lastra, Silvia
Piazzon, Nathalie
Santos, Rita
von Loga, Katharina
Hoffmann, Caroline
Coukos, George https://orcid.org/0000-0001-8813-7367
Peters, Solange https://orcid.org/0000-0002-0412-7143
Soumelis, Vassili
Durand, Eric Yves
de Leval, Laurence https://orcid.org/0000-0003-3994-516X
Gottardo, Raphael https://orcid.org/0000-0002-3867-0232
Homicsko, Krisztian
Madissoon, Elo https://orcid.org/0000-0003-2405-4911
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030_215550)
- License Information
-
More Information
Article History
Received: 1 October 2024
Accepted: 2 April 2025
First Online: 12 May 2025
Competing interests
: E.M., A.E.P., Q.B., S.C., E.Y.D., R.San., K.v.L., R.D., C.Ha., S.L.L., A. K., V.S. are Owkin employees and shareholders. C. Ho. is an Owkin employee and a consultant for Nanobiotix. R.G. has received consulting income from Takeda, Arcellx, GSK, and Sanofi; declares ownership in Ozette Technologies; and has received research funding from 10X Genomics through his employer, the CHUV. G.C. has received honoraria from Bristol-Myers Squibb. The Lausanne University Hospital (CHUV) has received honoraria for advisory services G.C. has provided to Iovance and EVIR. G.C. has received royalties from the University of Pennsylvania for CAR T cell therapy licensed to Novartis and Tmunity Therapeutics, and from the Ludwig Institute for Cancer Research, the University of Lausanne and the CHUV, for NeoTIL intellectual property previously licensed to Tigen Pharma. S.P. has received educational grants, provided consultation, attended advisory boards, and/or delivered lectures for the following organizations, from which S.P. has received honoraria (all fees directed to their institution): AbbVie, Amgen, Arcus, AstraZeneca, Bayer, Beigene, BioNTech, BerGenBio, Bicycle Therapeutics, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F-Star, Foundation Medicine, Genmab, Genzyme, Gilead, GSK, Hutchmed, Illumina, Incyte, Ipsen, iTeos, Janssen, Qlucore, Merck Sharp and Dohme, Merck Serono, Merrimack, Mirati, Nuvation Bio, Nykode Therapeutics, Novartis, Novocure, Pharma Mar, Promontory Therapeutics, Pfizer, Regeneron, Roche/Genentech, Sanofi, Seattle Genetics, Takeda, and Zymeworks. S.P. has spoken at company-organized public events for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Foundation Medicine, GSK, Illumina, Ipsen, Merck Sharp and Dohme, Mirati, Novartis, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, and Takeda. Additionally, S.P. has served as a principal investigator for trials sponsored by Amgen, Arcus, AstraZeneca, Beigene, Bristol-Myers Squibb, Eli Lilly, GSK, iTeos, Merck Sharp and Dohme, Mirati, Pharma Mar, Promontory Therapeutics, Roche/Genentech, and Seattle Genetics, with institutional financial support for these clinical trials.
